Here is the design of a clinical trial:

Official Title: Instantaneous Wave-free Ratio Guided Multi-vessel revascularizatiOn During Percutaneous Coronary intervEntion for Acute myocaRdial iNfarction (iMODERN)

Included conditions:
- Acute Myocardial Infarction
- Multi Vessel Coronary Artery Disease

Study Armgroups:
- {'label': 'Active iFR-guided revascularization', 'type': 'EXPERIMENTAL', 'description': 'Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment', 'interventionNames': ['Diagnostic Test: iFR']}
- {'label': 'Deferred CMR-guided revascularization', 'type': 'ACTIVE_COMPARATOR', 'description': 'Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging', 'interventionNames': ['Diagnostic Test: CMR']}

Interventions:
- {'type': 'DIAGNOSTIC_TEST', 'name': 'iFR', 'description': 'Treatment guided by instantaneous wave-free ratio', 'armGroupLabels': ['Active iFR-guided revascularization']}
- {'type': 'DIAGNOSTIC_TEST', 'name': 'CMR', 'description': 'Treatment guided by stress perfusion CMR', 'armGroupLabels': ['Deferred CMR-guided revascularization']}

Primary Outcomes:
- {'measure': 'Composite end point of Major Adverse Cardiac Events', 'description': 'All-cause death, recurrent myocardial infarction and hospitalization for heart failure', 'timeFrame': '3 years'}

Please estimate the sample size based on the assumption: 
80% power, two-sided alpha level of 5%
Sample size calculation
        The study is powered to assess and compare the difference in the primary end point between the iFR-guided revascularisation during index procedure group vs the CMR-guided approach after 12âmonths. Assuming a 16% incidence of the primary end point in the CMR-guided group based on previous literature,6 153 primary endpoint events are needed and should be provided by 1146 patients in order to provide the study with 80% power to detect a relative risk reduction of 35%, implying an HR of 0.63, at a two-sided alpha level of 5%.